BIOBANK  login

Indivumed and CELLphenomics announce their new partnership

Berlin/Hamburg, Germany, 9-7-2022

The Indivumed GmbH and the CELLphenomics GmbH today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.